Small study supports longer dosing interval for Pfizer vaccine

26 July 2021

Scientists in the UK have identified what they say is the ideal dosage regimen for the coronavirus vaccine developed by BioNTech (Nasdaq: BNTX) and Pfizer (NYSE: PFE).

Funded by the Department of Health and Social Care (DHSC), the PITCH study compared different dosing schedules of BNT162b2, also known as Comirnaty in Europe, in order to evaluate the impact on antibody levels and T-cell production.

While the drugmakers have gained approval on the basis of a three-week interval, the UK’s Joint Committee on Vaccination and Immunization (JCVI) has recommended a 12-week gap, partly to enable faster coverage of the population with at least one dose.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK